Abstract
BackgroundInterleukin (IL)‐34 is a recently discovered pro‐inflammatory cytokine and is a vital regulator in different tumor types. However, the function of IL‐34 in thyroid carcinoma has yet to be investigated. In this study, we analyzed the expression of IL‐34 in human papillary thyroid cancer (PTC) samples and determined its effects on the proliferation and apoptosis of PTC cells.MethodsWe examined the expression of IL‐34 in serum and tissue samples of patients with PTC by Western blotting and ELISA assay and analyzed its association with clinicopathological features including tumor size, tumor node metastasis (TNM) stage, and lymph node metastasis (LNM). We selected TPC1 and K1 for knockdown or overexpressing of IL‐34 via small interference RNA transfection. The proliferation of PTC cells was evaluated by CCK8 assay. We further investigated the role of IL‐34 in apoptosis by flow cytometry and studied the protein levels of epithelial‐mesenchymal transition (EMT) biomarkers, phosphorylated extracellular‐regulated kinase (ERK), and total‐ERK (t‐ERK) by Western blotting.ResultsOur results show that IL‐34 is significantly upregulated in serum and tissue samples from patients with PTC. IL‐34 promotes the proliferation and suppresses apoptosis in PTC cells. In addition, IL‐34 can promote the EMT and activate ERK signaling pathway in PTC cells.ConclusionThis study provides novel evidence that IL‐34 serves as an oncogene in PTC. IL‐34 promotes proliferation, EMT phenotype, and ERK signaling pathway and inhibits apoptosis in PTC cells. Therefore, IL‐34 may be a potent therapeutic target for the treatment of PTC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have